About this trial
The purpose of this study is to evaluate whether the use of antibiotic-coated (triclosan) braided sutures is non-inferior or potentially superior to standard monofilament sutures in patients with prosthetic joint infections (PJIs) managed with the DAIR protocol. Several studies in various surgical specialties have demonstrated the effectiveness and non-inferiority of triclosan-coated braided sutures in infected surgical cases, and the study intends to transpose this idea to the management of prosthetic joint infections. Monofilament sutures are the present standard of care in any infected joint case due their lower surface area for bacterial harborization, though surgeons sacrifice mechanical integrity and comfortability with the closure in the process. By demonstrating the safety of antibiotic -coated braided sutures, surgeons will no longer have to make this compromise.
Eligibility criteria
Qualifiers
Age ≥18 years
Willing and able to provide informed consent
Primary Total Hip Arthroplasty or Total Knee Arthroplasty with Prosthetic Joint Infection Musculoskeletal Infection Society (MSIS) criteria
Prosthetic Joint Infection Treated with Debridement, Antibiotics, Implant Retention
Disqualifiers
Staphylococcus aureus bacteremia
Mycobacterial, fungal, or parasitic infection
Concurrent infection needing prolonged Intravenous therapy
Septic shock/systemic illness needing IV therapy
Trial design
Treatments tested in this trial
- VICRYL™ Plus (Coated VICRYL™ Plus Antibacterial)
- Polydioxanone (PDS™ II ) Sterile Synthetic Absorbable Surgical Suture-Monofilament